Clinical Trials Browser

Phase 1 × Interventional × patritumab deruxtecan × Clear all

NCT03260491 2026-03-05

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04676477 2025-06-22

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis